Literature DB >> 12920227

c-Kit is not expressed in malignant mesothelioma.

Andrew E Horvai1, Li Li, Zhidong Xu, Miranda J Kramer, David M Jablons, Patrick A Treseler.   

Abstract

Overexpression of KIT protein (CD117), the product of the c-kit gene, has been shown to have important prognostic and therapeutic implications for a number of malignant neoplasms. Previous studies have shown conflicting results regarding the expression of c-kit in malignant mesothelioma. To determine whether malignant mesothelioma expresses KIT, immunohistochemistry and RT-PCR were used to analyze archived tissue from 37 cases of mesothelioma. Although a subset of mesotheliomas demonstrated specific staining with the DAKO anti-KIT antibody, in each case staining was nuclear. We could not detect c-kit mRNA by a sensitive RT-PCR assay, even in cases with strong nuclear staining. Furthermore, a second anti-KIT antibody (Cell-Marque) only demonstrated staining in a single mesothelioma case and in none of the cases that demonstrated nuclear staining. We conclude that immunoreactivity for KIT in mesothelioma does not represent expression of the c-kit gene and may represent antibody cross-reaction with nuclear proteins. Our results raise doubt about previously reported expression of KIT in mesothelioma and consequently, the applicability of therapeutic agents that target the kinase activity of KIT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920227     DOI: 10.1097/01.MP.0000083647.69123.5C

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.

Authors:  Christos G Tsokos; Gregor Krings; Funda Yilmaz; Linda D Ferrell; Ryan M Gill
Journal:  Hum Pathol       Date:  2016-07-07       Impact factor: 3.466

2.  From blood islands to blood vessels: morphologic observations and expression of key molecules during hyaloid vascular system development.

Authors:  D Scott McLeod; Takuya Hasegawa; Takayuki Baba; Rhonda Grebe; Ines Galtier d'Auriac; Carol Merges; Malia Edwards; Gerard A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-03       Impact factor: 4.799

3.  Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

Authors:  Pietro Bertino; Camillo Porta; Dario Barbone; Serena Germano; Sara Busacca; Sabrina Pinato; Giancarlo Tassi; Roberto Favoni; Giovanni Gaudino; Luciano Mutti
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

4.  Diagnostic challenges of motility disorders: optimal detection of CD117+ interstitial cells of Cajal.

Authors:  Megan M Garrity; Simon J Gibbons; Thomas C Smyrk; Jean Marie Vanderwinden; Pedro Julian Gomez-Pinilla; Anoop Nehra; Matthew Borg; Gianrico Farrugia
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

5.  Identification of a novel autoantibody against self-vimentin specific in secondary Sjögren's syndrome.

Authors:  Yu-Hui Li; Ya-Ping Gao; Jie Dong; Lian-Jie Shi; Xiao-Lin Sun; Ru Li; Xue-Wu Zhang; Yu Liu; Li Long; Jing He; Qun-Jie Zhong; Eric Morand; Guang Yang; Zhan-Guo Li
Journal:  Arthritis Res Ther       Date:  2018-02-12       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.